Search Results
Endocrine Oncology Branch, Geisel School of Medicine at Dartmouth, National Institutes of Health, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Search for other papers by Amit Mehta in
Google Scholar
PubMed
Search for other papers by Lisa Zhang in
Google Scholar
PubMed
Search for other papers by Myriem Boufraqech in
Google Scholar
PubMed
Search for other papers by Yaqin Zhang in
Google Scholar
PubMed
Search for other papers by Dhaval Patel in
Google Scholar
PubMed
Search for other papers by Min Shen in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
Introduction Thyroid cancer is the most common endocrine malignancy ( Howlader et al . 2013 ). Anaplastic thyroid cancer (ATC) accounts for 1–2% of all thyroid cancers, but is the most common cause of thyroid-cancer-related deaths ( Kebebew et al
Search for other papers by Francesca Marano in
Google Scholar
PubMed
Search for other papers by Roberto Frairia in
Google Scholar
PubMed
Search for other papers by Letizia Rinella in
Google Scholar
PubMed
Search for other papers by Monica Argenziano in
Google Scholar
PubMed
Search for other papers by Benedetta Bussolati in
Google Scholar
PubMed
Search for other papers by Cristina Grange in
Google Scholar
PubMed
Search for other papers by Raffaella Mastrocola in
Google Scholar
PubMed
Search for other papers by Isabella Castellano in
Google Scholar
PubMed
Search for other papers by Laura Berta in
Google Scholar
PubMed
Search for other papers by Roberta Cavalli in
Google Scholar
PubMed
Search for other papers by Maria Graziella Catalano in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancer (ATC) is one of the most lethal cancers, its median survival being only 5 months, and 1-year survival being less than 20% ( Smallridge & Copland 2010 ). To date, a standard therapy for ATC does not exist
Search for other papers by Xuguang Zhu in
Google Scholar
PubMed
Search for other papers by Sunmi Park in
Google Scholar
PubMed
Search for other papers by Woo Kyung Lee in
Google Scholar
PubMed
Search for other papers by Sheue-yann Cheng in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancer (ATC) is one of the most aggressive endocrine malignancies. Patients rarely survive more than 1 year after diagnosis and have very limited treatment options. In addition to genetic alterations, aberrant
Search for other papers by Robert C Smallridge in
Google Scholar
PubMed
Search for other papers by Laura A Marlow in
Google Scholar
PubMed
Search for other papers by John A Copland in
Google Scholar
PubMed
, Rocha et al . (2003) evaluated 17 poorly differentiated (but no anaplastic) thyroid cancers. They found loss of cadherin 1, type 1, E-cadherin (epithelial) membrane expression, but no nuclear localization of catenin (cadherin-associated protein), beta
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Jiajun Wu in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Juyong Liang in
Google Scholar
PubMed
Search for other papers by Ruiqi Liu in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Tian Lv in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Kangyin Fu in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Liehao Jiang in
Google Scholar
PubMed
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Wenli Ma in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Yan Pan in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Zhuo Tan in
Google Scholar
PubMed
Search for other papers by Qing Liu in
Google Scholar
PubMed
Search for other papers by Weihua Qiu in
Google Scholar
PubMed
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Search for other papers by Minghua Ge in
Google Scholar
PubMed
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Clinical Research Center for Cancer of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Department of Thyroid and Breast Surgery, Zhejiang Provincial People’s Hospital Bijie Hospital, Bijie, Guizhou, China
Search for other papers by Jiafeng Wang in
Google Scholar
PubMed
. (D) and (E) Images and quantifications of TUNEL assay and IHC staining of Ki67, P62, LC3B, HO-1, and GPX4. (F) Schematic of anlotinib-mediated autophagy-ferroptosis signaling in anaplastic thyroid cancer. Tumorigenic markers were assayed by
Search for other papers by W-B Zhong in
Google Scholar
PubMed
Search for other papers by Y-C Liang in
Google Scholar
PubMed
Search for other papers by C-Y Wang in
Google Scholar
PubMed
Search for other papers by T-C Chang in
Google Scholar
PubMed
Search for other papers by W-S Lee in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancer is one of the most aggressive malignant tumors. Patients with anaplastic thyroid cancer have a poor prognosis with a mean survival time of 2–6 months ( Tan et al. 1995 ). It is generally
Search for other papers by Eleanor L Woodward in
Google Scholar
PubMed
Search for other papers by Andrea Biloglav in
Google Scholar
PubMed
Search for other papers by Naveen Ravi in
Google Scholar
PubMed
Search for other papers by Minjun Yang in
Google Scholar
PubMed
Search for other papers by Lars Ekblad in
Google Scholar
PubMed
Search for other papers by Johan Wennerberg in
Google Scholar
PubMed
Search for other papers by Kajsa Paulsson in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancer (ATC) is a rare and lethal disease, accounting for only 1–5% of all thyroid malignancies and yet being responsible for approximately 50% of deaths attributed to thyroid cancer ( Kebebew et al . 2005
Search for other papers by M Onda in
Google Scholar
PubMed
Search for other papers by M Emi in
Google Scholar
PubMed
Search for other papers by A Yoshida in
Google Scholar
PubMed
Search for other papers by S Miyamoto in
Google Scholar
PubMed
Search for other papers by J Akaishi in
Google Scholar
PubMed
Search for other papers by S Asaka in
Google Scholar
PubMed
Search for other papers by K Mizutani in
Google Scholar
PubMed
Search for other papers by K Shimizu in
Google Scholar
PubMed
Search for other papers by M Nagahama in
Google Scholar
PubMed
Search for other papers by K Ito in
Google Scholar
PubMed
Search for other papers by T Tanaka in
Google Scholar
PubMed
Search for other papers by T Tsunoda in
Google Scholar
PubMed
thyroid gland. Anaplastic thyroid cancer (ATC) is thought to arise mainly from a background of differentiated (papillary or follicular) cancer, on the basis of clinicopathological observations that ATCs are often accompanied by such cells, and because
Search for other papers by Yannick Arlot-Bonnemains in
Google Scholar
PubMed
Search for other papers by Enke Baldini in
Google Scholar
PubMed
Search for other papers by Benedicte Martin in
Google Scholar
PubMed
Search for other papers by Jean-Guy Delcros in
Google Scholar
PubMed
Search for other papers by Matteo Toller in
Google Scholar
PubMed
Search for other papers by Francesco Curcio in
Google Scholar
PubMed
Search for other papers by Francesco S Ambesi-Impiombato in
Google Scholar
PubMed
Search for other papers by Massimino D'Armiento in
Google Scholar
PubMed
Search for other papers by Salvatore Ulisse in
Google Scholar
PubMed
follicular epithelial origin . Journal of the Chinese Medical Association 69 74 – 79 . Kurebayashi J Okubo S Yamamoto Y Ikeda M Tanaka K Otsuki T Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer
Search for other papers by M Celano in
Google Scholar
PubMed
Search for other papers by S Schenone in
Google Scholar
PubMed
Search for other papers by D Cosco in
Google Scholar
PubMed
Search for other papers by M Navarra in
Google Scholar
PubMed
Search for other papers by E Puxeddu in
Google Scholar
PubMed
Search for other papers by L Racanicchi in
Google Scholar
PubMed
Search for other papers by C Brullo in
Google Scholar
PubMed
Search for other papers by E Varano in
Google Scholar
PubMed
Search for other papers by S Alcaro in
Google Scholar
PubMed
Search for other papers by E Ferretti in
Google Scholar
PubMed
Search for other papers by G Botta in
Google Scholar
PubMed
Search for other papers by S Filetti in
Google Scholar
PubMed
Search for other papers by M Fresta in
Google Scholar
PubMed
Search for other papers by M Botta in
Google Scholar
PubMed
Search for other papers by D Russo in
Google Scholar
PubMed
-inhibiting activity ( Carraro et al . 2004 , Schenone et al . 2004 b , Angelucci et al . 2006 ). In the present study, we tested the effects of two of these compounds, Si 34 and Si 35 ( Fig. 1 ), on the growth rate and the viability of anaplastic thyroid cancer